de Araujo Sensever Felipe, Jardim Luísa Comerlato, Ferrazzo Kívia Linhares, Skupien Jovito Adiel, Antoniazzi Raquel Pippi
Franciscan University (UFN), Santa Maria, Brazil.
Department of Pathology, Federal University of Santa Maria (UFSM), Santa Maria, Brazil.
Support Care Cancer. 2022 Oct;30(10):8193-8199. doi: 10.1007/s00520-022-07271-4. Epub 2022 Jul 7.
Investigate the effect of tamoxifen on the occurrence of tooth loss (TL) in breast cancer (BC) survivors.
A cross-sectional study was conducted with 140 BC survivors using tamoxifen therapy. Sociodemographic, medical, and dental data were evaluated. TL was determined using the M component of the Decayed, Missing and Filled Teeth (DMFT) index. Logistic regression models were run to determine associations between the independent variables and outcome (TL).
Mean TL was 12.96 (SD 8.88). Only three participants had lost no teeth and 10.7% were completely edentulous. Participants who used tamoxifen for more than 1 year had a higher mean missing teeth (13.99 vs. 10.45; P = 0.030). After the adjustments, the occurrence of more than 12 missing teeth was 2.75-fold higher among women who used tamoxifen for more than 1 year (95% CI: 1.06-7.12). Moreover, age over 65 years, referral for treatment by the public healthcare system, less use of dental services, xerostomia, and a lower occurrence of dental caries remained associated with the loss of more than 12 teeth.
Longer use of tamoxifen was associated with greater tooth loss in breast cancer survivors.
Based on estimates of the increase in cases of breast cancer, the prolonged use of tamoxifen for the treatment of this disease can exert an impact on oral health through the occurrence of tooth loss. These findings can contribute to the planning and implementation of oral health care and prevention strategies for such patients.
研究他莫昔芬对乳腺癌（BC）幸存者牙齿脱落（TL）发生率的影响。
对140例接受他莫昔芬治疗的BC幸存者进行了一项横断面研究。评估了社会人口统计学、医学和牙科数据。使用龋失补指数（DMFT）的M部分确定TL。运行逻辑回归模型以确定自变量与结果（TL）之间的关联。
平均TL为12.96（标准差8.88）。只有3名参与者没有牙齿脱落，10.7%的人完全无牙。使用他莫昔芬超过1年的参与者平均缺失牙齿数更高（13.99对10.45；P = 0.030）。调整后，使用他莫昔芬超过1年的女性中，缺失超过12颗牙齿的发生率高出2.75倍（95%置信区间：1.06 - 7.12）。此外，65岁以上的年龄、由公共医疗系统转诊治疗、较少使用牙科服务、口干症以及较低的龋齿发生率仍然与缺失超过12颗牙齿有关。
在乳腺癌幸存者中，较长时间使用他莫昔芬与更多的牙齿脱落有关。
根据乳腺癌病例增加的估计，长期使用他莫昔芬治疗这种疾病可通过牙齿脱落对口腔健康产生影响。这些发现有助于为此类患者规划和实施口腔保健及预防策略。
